ASTHMA DRUG NOT PERFORMANCE ENHANCING

Spiering, B. A., Baumann, J. M., & Rundell, K. W. (2004). Montelukast has no ergogenic effects during cycling in sub-freezing conditions. Medicine and Science in Sports and Exercise, 36(5), Supplement abstract 119.

Montelukast (ML), a leukotriene receptor antagonist, attenuates exercise-induced bronchoconstriction (EIB) and its symptoms (p. S13). This investigation evaluated its effect on exercise performance. Athletes (M = 27; F = 3) performed a 6-min time-trial in sub-freezing conditions (-2.5C). The exercise was performed under the ML and a control placebo condition.

No significant differences in the work produced were demonstrated between groups. When Ss were grouped according to EIB status, there still was no effect or difference.

Implication. A single dose of ML for EIB has no effect upon high-intensity cycling performance in the cold.

Return to Table of Contents for this issue.